Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Dec 11 2020

Full Issue

LabCorp Gets Home COVID Test Approved

The FDA issues an emergency use authorization for a COVID test that can be purchased without a prescription. Erectile dysfunction drug is recalled; Amazon's new band gets a mixed review.

Genomweb: LabCorp Receives Approval For The Industry's First Over-The-Counter Home COVID-19 Test

LabCorp said on Wednesday that it has received Emergency Use Authorization for an over-the-counter version of its COVID-19 home test. With the EUA, LabCorp is able to sell the test kit directly to consumers without requiring a prescription. The kit is the first over-the-counter at-home collection kit for SARS-CoV-2 to receive EUA. (Bonislawski, 12/10)

In other pharmaceutical and biotech news —

The Hill: Erectile Dysfunction Drug Packaged With Antidepressant In 'Product Mix-Up' 

Pharmaceutical distributor AvKare issued a voluntary recall of 100 mg tablets of both sildenafil, an erectile disfunction medication, and trazodone, an antidepressant, after a mix-up led to some of the prescription drugs being packaged together. “These products have been recalled due to a product mix-up of the listed two separate products inadvertently packaged together during bottling at a 3rd party facility,” the company said in a Wednesday announcement. (Pitofsky, 12/10)

Stat: Boehringer Warns FDA A Single Word Threatens Biosimilar Competition

Arguing the Food and Drug Administration is precluding competition for biosimilar manufacturers, Boehringer Ingelheim has petitioned the agency to alter its interpretation of the word “strength” found in a federal law that has made it possible to sell these medicines. The move reflects a wonky, behind-the-scenes dispute that, nonetheless, holds potentially great significance for the burgeoning growth of biosimilar treatments in the U.S., which is expected to reach $80 billion in aggregate sales over the next five years, according to one recent forecast. (Silverman, 12/10)

The Washington Post: Amazon’s Halo Band Wearable Tracks Your Voice And Body Fat, But Isn’t Helpful 

Amazon has a new health-tracking bracelet with a microphone and an app that tells you everything that’s wrong with you. You haven’t exercised or slept enough, reports Amazon’s $65 Halo Band. Your body has too much fat, the Halo’s app shows in a 3-D rendering of your near-naked body. (Fowler and Kelly, 12/10)

Boston Globe: Startup Backed By Third Rock Launches With $81 Million To Go After ALS

A new biotechnology company was launched Thursday in Cambridge with $81 million in funding, joining a growing number of biotechs in the area that are based on an emerging field in cell biology. Faze Medicines will work on “biomolecular condensates,” which it believes can be studied to develop drugs that could slow, halt, or reverse certain diseases. Condensates are membrane-less organelles, or clusters of molecules such as proteins and nucleic acids, that help cells perform vital functions. (Gardizy, 12/10)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF